Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and Objective. Omalizumab is a recombinant, humanized, monoclonal anti-immunoglobulin E (IgE) antibody, developed for the treatment of IgE-mediated diseases. In children with allergic asthma, it was shown to reduce the requirement for inhaled corticosteroids while protecting against disease exacerbation. Here we report the effects of treatment with omalizumab on asthma-related quality of life (AQoL) in children with allergic asthma. Methods. This evaluation was part of a previously reported 28-week, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks) in children with allergic asthma who were well controlled on daily treatment with inhaled corticosteroids. Dosage of beclomethasone dipropionate was kept constant for 16 weeks (steroid-stable phase), then reduced over 8 weeks to the minimum effective dose (steroid-reduction phase). This dose was then maintained for the final 4 weeks. The Pediatric Asthma Quality of Life Questionnaire (PAQLQ) was administered at baseline, week 16, and week 28. Results. Baseline demographics, PAQLQ scores, and other data were comparable for the 2 treatment groups. At the end of the steroid-reduction phase, patients in the omalizumab-treated group reported significant improvements in the “activities” and “symptoms” domain scores as well as overall AQoL compared with placebo. More patients in the omalizumab group achieved clinically relevant (≥0.5) changes in PAQLQ scores during the course of the study, and this difference was significant for activities and overall AQoL. Conclusion. Omalizumab improves AQoL in children with allergic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nelson, H. S., Szefler, S. J., Jacobs, J., Huss, K., Shapiro, G., & Sternberg, A. L. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70287-3 · Cited by 178
Cited by
Omalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
De Civita, M., Regier, D., Alamgir, A. H., Anis, A. H., FitzGerald, M. J., & Marra, C. A. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523070-00003 · Cited by 257
Holgate, S. T., Djukanović, R., Casale, T., & Bousquet, J. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02191.x · Cited by 254
Guilbert, T. W., Bacharier, L. B., & Fitzpatrick, A. M. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.06.022 · Cited by 216
Ramratnam, S. K., Bacharier, L. B., & Guilbert, T. W. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.04.031 · Cited by 119
Metadata
- Authors
- Lemanske, R. F., Nayak, A., McAlary, M., Everhard, F., Fowler-Taylor, A., & Gupta, N.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2002-11-01
- Volume
- 110
- Issue
- 5
- Pages
- e55-e55
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2101548824
- Cited by
- 150
- References
- 1
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma. https://app.cochat.ai/papers/10.1542/peds.110.5.e55
- The paper
- Lemanske, R. F., Nayak, A., McAlary, M., Everhard, F., Fowler-Taylor, A., & Gupta, N. (2002). Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma. Pediatrics. https://doi.org/10.1542/peds.110.5.e55
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.